Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Mixed-methods validation study of two screening tools in a single centre with small qualitative sample (n=20), generating hypothesis that multi-measure approach may be needed rather than establishing superior measurement strategy.
Expert Review of Pharmacoeconomics & Outcomes Research
A single-center retrospective pharmacoeconomic model with simulated dosing strategy and no clinical outcome data; findings require prospective validation before implementation.
A White Paper outlining strategic recommendations and a roadmap for international registry collaboration in lymphoma, not reporting original research findings or clinical trial data.
Retrospective registry analysis describing focal therapy adoption patterns and characterizing use across risk groups, but providing no efficacy or safety outcomes to support clinical decision-making.
Large retrospective cohort study with 2.7 million patients from a national database showing consistent, statistically significant trends in prolonged cancer surgery waiting times across six cancer types from 2012–2023, with identified risk factors and predictors.
A retrospective cost-effectiveness analysis in a single-centre Turkish cohort that confirms ODX RS reduces unnecessary chemotherapy and improves cost-effectiveness compared to clinicopathological assessment alone, consistent with TAILORx trial findings but without new primary efficacy data.
A single-centre modelling study using a hybrid decision tree and Markov model with assumed parameters, not a clinical trial; provides economic perspective but lacks empirical validation of clinical inputs and generalizability.
A cost-effectiveness model using a partitioned survival framework in a single health-system context; lacks clinical trial data underpinning the model and does not report the source evidence for efficacy or survival inputs.